Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Silvio Garattini

Showing results (21-30 of 165) with videos related to

Pageof 17
Sort By:
The New England Journal of Medicine|January 19, 2018
Noninferiority TrialsSilvio Garattini, Vittorio Bertele’
Recenti Progressi in Medicina|May 19, 2004
[A model for integrating biomedical research information]Eugenio Santoro, Silvio Garattini
Journal of Hepatology|August 12, 2009
Ethics in clinical researchSilvio Garattini, Vittorio Bertele'
BMJ (Clinical Research Ed.)|April 1, 2010
Europe's opportunity to open up drug regulationSilvio Garattini, Vittorio Bertele'
Expert Review of Pharmacoeconomics & Outcomes Research|October 8, 2009
Toward new legislation on drugs in EuropeSilvio Garattini, Vittorio Bertele'
European Journal of Internal Medicine|June 27, 2018
A meritorious move against homeopathySilvio Garattini, Vittorio Bertele'
British Journal of Clinical Pharmacology|November 26, 2004
Risk:benefit assessment of old medicinesSilvio Garattini, Vittorio Bertelé
BMJ (Clinical Research Ed.)|August 3, 2002
Efficacy, safety, and cost of new anticancer drugsSilvio Garattini, Vittorio Bertele
BMJ (Clinical Research Ed.)|October 8, 2010
Rosiglitazone and the need for a new drug safety agencySilvio Garattini, Vittorio Bertele'
BMJ (Clinical Research Ed.)|April 2, 2009
Patients and the public deserve big changes in evaluation of drugsSilvio Garattini, Iain Chalmers
Pageof 17

Showing results (21-30 of 165) with videos related to

Sort By:
Pageof 17
The New England Journal of Medicine|January 19, 2018
Noninferiority TrialsSilvio Garattini, Vittorio Bertele’
Recenti Progressi in Medicina|May 19, 2004
[A model for integrating biomedical research information]Eugenio Santoro, Silvio Garattini
Journal of Hepatology|August 12, 2009
Ethics in clinical researchSilvio Garattini, Vittorio Bertele'
BMJ (Clinical Research Ed.)|April 1, 2010
Europe's opportunity to open up drug regulationSilvio Garattini, Vittorio Bertele'
Expert Review of Pharmacoeconomics & Outcomes Research|October 8, 2009
Toward new legislation on drugs in EuropeSilvio Garattini, Vittorio Bertele'
European Journal of Internal Medicine|June 27, 2018
A meritorious move against homeopathySilvio Garattini, Vittorio Bertele'
British Journal of Clinical Pharmacology|November 26, 2004
Risk:benefit assessment of old medicinesSilvio Garattini, Vittorio Bertelé
BMJ (Clinical Research Ed.)|August 3, 2002
Efficacy, safety, and cost of new anticancer drugsSilvio Garattini, Vittorio Bertele
BMJ (Clinical Research Ed.)|October 8, 2010
Rosiglitazone and the need for a new drug safety agencySilvio Garattini, Vittorio Bertele'
BMJ (Clinical Research Ed.)|April 2, 2009
Patients and the public deserve big changes in evaluation of drugsSilvio Garattini, Iain Chalmers
Pageof 17